1. REGEN-007 results show significant kidney function improvement in Group 1. 2. 78% reduction in eGFR decline was statistically significant (p<0.001). 3. Safety profile of rilparencel remains consistent with previous studies. 4. FDA Type B meeting planned to confirm eGFR slope as a surrogate endpoint. 5. ProKidney targets accelerated approval for rilparencel to address CKD market.

1. LogProstyle announced a share repurchase program for $543,455. 2. Program includes repurchase of up to 1,086,910 common shares. 3. Acquisitions are set from July 1, 2025, to June 30, 2026. 4. The program aims to enhance shareholder value through disciplined capital allocation. 5. LGPS commits to innovative and sustainable lifestyle projects.

1. LGPS reported a 46% revenue increase in fiscal year 2025. 2. Net income more than doubled, reaching JPY754 million (US$5 million). 3. Real estate revenue surged 52%, driven by increased unit sales. 4. Company's hotel revenue rose 20% with improved occupancy rates. 5. LGPS expanded globally with new US and Dubai subsidiaries.

1. RxSight expects Q2 2025 revenue of $33.6M, down 4% YoY. 2. LAL sales fell 1%; LDD sales dropped 45% Q/Q. 3. 2025 revenue guidance reduced to $120M-$130M from $160M-$175M. 4. Gross margin guidance increased to 72%-74%; operating expenses raised. 5. CEO emphasizes customer support for better outcomes and adoption.

1. Bivamelagon achieved significant BMI reductions of -9.3% and -7.7%. 2. Post-hoc analysis shows bivamelagon's effectiveness comparable to setmelanotide. 3. Patients reported a mean reduction of -2.8 points in hunger scores. 4. Rhythm plans to request FDA meeting for Phase 3 trial in obesity. 5. Company will present findings at The Endocrine Society’s Annual Meeting.

1. Bezuclastinib shows significant symptom score improvement in NonAdvSM patients. 2. 87.4% of treated patients had over 50% reduction in serum tryptase. 3. NDA submission for bezuclastinib to FDA expected by end of 2025. 4. Cogent maintains a strong financial position with $237 million cash. 5. Top-line results from related trials PEAK and APEX expected in late 2025.

1. Ferrero to acquire WK Kellogg Co for $23.00 per share cash. 2. Transaction reflects 40% premium over recent trading price of KLG shares. 3. Acquisition enhances Ferrero's portfolio with iconic breakfast cereal brands. 4. WK Kellogg Co expects net sales of $610-615 million for Q2 2025. 5. The deal is likely to close in the second half of 2025.

1. WK Kellogg shares jumped over 50% on acquisition news. 2. Ferrero may finalize a $3 billion purchase of WK Kellogg soon. 3. Kellanova separated from WK Kellogg in 2023 amidst market shifts. 4. Consumer preferences are shifting towards healthier breakfast options. 5. The deal signifies increasing consolidation in the packaged food sector.

1. KALV's EKTERLY approved as first oral on-demand HAE treatment. 2. EKTERLY offers rapid symptom relief, transforming HAE management. 3. Launch of EKTERLY begins immediately; prescriptions available today. 4. Significant safety profile established through robust clinical trials. 5. KalVista emphasizes commitment to HAE community via patient support program.

1. HELE reported a 10.8% drop in net sales to $371.7 million. 2. GAAP loss per share reached $19.65, significantly down from earnings per share. 3. Non-cash asset impairment of $414.4 million heavily impacted operating results. 4. CEO search is ongoing, with interim CEO focusing on core business improvements. 5. Tariff impacts accounted for significant revenue decline; mitigation efforts remain in progress.